These have included the development of a receptor tyrosine kinase inhibitor for canine mast cell tumors and the production of a PCR assay to monitor the chemotherapeutic response of canine high-grade B-cell lymphomas. This evidence concerns the gene NTRK1 and B-cell non-Hodgkin lymphoma.